Although during the collection of both registries guidelines for the treatment of heart failure have changed and a variety of new drugs have been implemented in therapy, such as angiotensin receptor neprilysin inhibitor, sodium-glucose co-transporter-2 inhibitors, a new class of beta-blockers and mineralocorticoid receptor antagonists, distinguished clusters seem to be resistant to that changes, because we have not included pre-admission treatment into cluster analysis. Here, NR3C2 is linked to heart failure.